АБРАМОВИЧИ Бернар (FR),БЕЙЕ Стефан (FR),ГОТЬЕ Жан-Клод (FR),ШАМБОННЕ Сандра (FR)
申请号：
RU2013126431/15
公开号：
RU2013126431A
申请日:
2011.11.10
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A pharmaceutical composition comprising at least one active substance selected from (i) 2-n-butyl-3- [4- (3-di-n-butylaminopropoxy) benzoyl] -5-metilsulfonamidobenzofurana in base form, (ii ) 2-n-butyl-3- [4- (3-di-n-butylaminopropoxy) benzoyl] -5-metilsulfonamidobenzofurana in the form of a pharmaceutically acceptable salt thereof, characterized in that it further comprises at least one amphiphilic lipid excipient with an HLB value in the range from 2 to 20.2. A composition according to claim 1, characterized in that the 2-n-butyl-3- [4- (3-di-n-butylaminopropoxy) benzoyl] -5-metilsulfonamidobenzofuran in the form of pharmaceutically acceptable salts selected from hydrochloride, 2-n-butyl- 3- [4- (3-di-n-butylaminopropoxy) benzoyl] -5-metilsulfonamidobenzofurana, fumarate 2-n-butyl-3- [4- (3-di-n-butylaminopropoxy) benzoyl] -5-oxalate and metilsulfonamidobenzofurana 2-n-butyl-3- [4- (3-di-n-butylaminopropoxy) benzoyl] -5-metilsulfonamidobenzofurana.3. A composition according to claim 1, characterized in that the active substance is selected from 2-n-butyl-3- [4- (3-di-n-butylaminopropoxy) benzoyl] -5-metilsulfonamidobenzofurana shaped base and hydrochloride of 2-n-butyl -3- [4- (3-di-n-butylaminopropoxy) benzoyl] -5-metilsulfonamidobenzofurana.4. A composition according to claim 1, characterized in that said composition further comprises at least one surfactant and / or at least one sorastvoritel.5. A composition according to claim 1, characterized in that the said amphiphilic lipid excipient with an HLB value ranging from 2 to 20 has a melting point below 50 ° C.6. A composition according to claim 1, characterized in that said lipid excipient is selected from substituted semisolid glyceride1. Фармацевтическая композиция, содержащая по меньше мере одно действующее вещество, выбранное из (i) 2-н-бутил-3-[4-(3-ди-н-бутиламинопропокси)бензоил]-5-метилсульфонамидобензофурана в форме основания, (ii) 2-н-бутил-3-[4-(3-ди-н-бутиламинопропокси)бензоил]-5-метилсульфонами
